Q2 2025 Viemed Healthcare Inc Earnings Call Transcript
Key Points
- Viemed Healthcare Inc (VMD) reported a 14.7% year-over-year revenue increase, driven entirely by organic growth.
- The company has achieved 17 consecutive quarters of growth in its core in-home ventilation business.
- The sleep therapy segment showed significant growth, with patient count up 15% sequentially and 51% year-over-year.
- The acquisition of Lehan Medical Equipment expands Viemed's market into maternal health, diversifying its patient base.
- Viemed's adjusted EBITDA grew 12% year-over-year, reflecting strong organic growth and contributions from all business segments.
- The gross margin declined year-over-year from 59.8% to 58.3%, although it showed a sequential improvement.
- The staffing business experienced a sequential slowdown due to softened labor demand, despite year-over-year growth.
- There is uncertainty regarding the potential return of competitive bidding for DME, which could impact future operations.
- The new NCD requires documentation and reporting of usage metrics, which could pose challenges for smaller operators.
- The company faces potential risks from tariffs, although no material impact has been observed yet.
Greetings, and welcome to the Viemed Healthcare second-quarter 2025 earnings call. (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Trae Fitzgerald. Thank you. You may begin.
Thank you, and good morning, everyone. We appreciate you joining us today. Please note that our remarks in this conference call may include forward-looking statements under the U.S. federal securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward-looking statements.
Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the security regulatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
